- Home
- PHAR vs NAGE Comparison
PHAR vs NAGE Comparison
Compare PHAR & NAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- NAGE
- Stock Information
- Founded
- PHAR 1988
- NAGE 1999
- Country
- PHAR Netherlands
- NAGE United States
- Employees
- PHAR N/A
- NAGE N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- NAGE Medicinal Chemicals and Botanical Products
- Sector
- PHAR Health Care
- NAGE Health Care
- Exchange
- PHAR Nasdaq
- NAGE Nasdaq
- Market Cap
- PHAR 951.7M
- NAGE 766.4M
- IPO Year
- PHAR N/A
- NAGE N/A
- Fundamental
- Price
- PHAR $13.14
- NAGE $7.11
- Analyst Decision
- PHAR Strong Buy
- NAGE Strong Buy
- Analyst Count
- PHAR 3
- NAGE 3
- Target Price
- PHAR $30.00
- NAGE $17.00
- AVG Volume (30 Days)
- PHAR 11.0K
- NAGE 1.2M
- Earning Date
- PHAR 11-06-2025
- NAGE 11-04-2025
- Dividend Yield
- PHAR N/A
- NAGE N/A
- EPS Growth
- PHAR N/A
- NAGE N/A
- EPS
- PHAR N/A
- NAGE 0.22
- Revenue
- PHAR $339,836,000.00
- NAGE $116,303,000.00
- Revenue This Year
- PHAR $17.70
- NAGE $29.51
- Revenue Next Year
- PHAR $12.25
- NAGE $20.55
- P/E Ratio
- PHAR N/A
- NAGE $33.78
- Revenue Growth
- PHAR 22.44
- NAGE 35.90
- 52 Week Low
- PHAR $7.31
- NAGE $3.49
- 52 Week High
- PHAR $17.08
- NAGE $14.69
- Technical
- Relative Strength Index (RSI)
- PHAR 42.37
- NAGE 36.00
- Support Level
- PHAR $13.08
- NAGE $7.23
- Resistance Level
- PHAR $14.10
- NAGE $7.70
- Average True Range (ATR)
- PHAR 0.52
- NAGE 0.29
- MACD
- PHAR -0.16
- NAGE 0.07
- Stochastic Oscillator
- PHAR 0.00
- NAGE 11.36
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About NAGE Niagen Bioscience Inc. Common Stock
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.